iThera Medical (ITHE) was founded in 2010 as a spin-off from Helmholtz Center Munich for Environmental Health (HMGU). The Company develops and markets biomedical imaging systems based on a novel biophotonic technology, Multispectral Optoacoustic Tomography (MSOT). ITHE holds exclusive license rights to all MSOT-related IP developed by the Institute of Biological and Medical Imaging (IBMI) at HMGU. Since 2010, ITHE has been selling successfully worldwide into the preclinical imaging market. Customer are laboratories in biomedical and pharma research that conduct small animal studies. ITHE has an established global distribution network for its preclinical systems with sales offices in Europe and the US and distributors covering all other major markets in Asia, Australia and South America. In 2013 the company built out its own production facilities and is now able to serve the growing global preclinical optoacoustic market. ITHE has a highly experienced team of currently 28 employees with expertise covering all aspects of optoacoustic technology, e.g., laser physics and fiberoptic light guides, data acquisition electronics, ultrasound detector design, and general electronic, electrical and mechanical capabilities. The company’s management team currently consists of the CEO (Christian Wiest), an experienced manager in the area of medical technology, and a Chief Commercial Officer (Dr. Philipp Bell) overseeing operations and finance. The two academic co-founders (Prof. Vasilis Ntziachristos, Leibniz Laureate 2013; Prof. Daniel Razansky) continue to pursue academic research on MSOT at HMGU and serve as advisors to ITHE.
iThera Medical offers the next generation in molecular imaging via MSOT – Multispectral Optoacoustic Tomography.
With its unique ability to accurately visualize and quantify tissue molecules, nanoparticles, biomarkers and optical agents, in vivo and in real time, through several centimeters of tissue, MSOT stands at the forefront of the next era in biomedical imaging.
Dr. Neal Burton
Dr. Neal Burton has been with iThera Medical since October 2010 and works as a Senior Application Specialist with MSOT customers worldwide. Before joining iThera Medical, Neal worked as post-doctoral researcher at Helmholtz Center Munich on developing applications for the first preclinical MSOT device, and as a post-doctoral fellow at the University of Wisconsin-Madison developing antioxidative therapies for chronic neurodegenerative diseases. Neal holds a PhD in Toxicology from the Johns Hopkins Bloomberg School of Public Health, where he received extensive training related to clinical studies, carcinogenesis, and biostatistics. He will perform MSOT scanning and data analysis, as well as give scientific input into the project.